Gilead's Got Game: Trodelvy Scores Big in Breast Cancer

Gilead Sciences’ announcement of the successful Phase III ASCENT-03 trial, in which Trodelvy (sacituzumab govitecan-hziy) demonstrated a significant improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mTNBC), represents a major development in the treatment of this aggressive disease.